Table 2 |
|||
|
Results of logistic regression of buprenorphine adoption on facility and state characteristics |
|||
| B |
95% CI |
OR |
|
|
|
|||
| Ownership/Profit Statusa |
|||
| Government owned |
-.457* |
(-.833, -.082) |
.63 |
| Private, non-profit |
-.605** |
(-.827, -.384) |
.55 |
| Facility Characteristics |
|||
| Based in a hospital |
.671** |
(.411, .931) |
1.96 |
| Opioid Treatment Program (OTP) |
.696** |
(.276, 1.115) |
2.00 |
| SA treatment is primary focus |
.014 |
(-.332, .359) |
|
| Offers detox |
1.959** |
(1.545, 2.374) |
7.09 |
| Outpatient only |
-.186* |
(-.343, -.028) |
.83 |
| Adolescent program |
-1.123** |
(-1.667, -.581) |
.33 |
| Accredited |
.307** |
(.114, .500) |
1.36 |
| Past-year admissions |
.0002** |
(.0001, .0003) |
1.00 |
| Located in a metropolitan area |
.541** |
(.243, .838) |
1.72 |
| Key Funding Sources |
|||
| Receives government funds |
-.306** |
(-.515, -.098) |
.74 |
| Accepts Medicaid |
.175 |
(-.110, .460) |
|
| Has managed care contract(s) |
.472** |
(.280, .665) |
1.60 |
| State-Level Variables |
|||
| SSA encourages use of buprenorphine |
.171 |
(-.098, .440) |
|
| Medicaid covers buprenorphine |
.081* |
(.011, .152) |
1.09 |
| McKelvey & Zavonia's R2 |
.364 |
||
| Model chisq (df) p |
778.51 (16) p < .001 |
||
|
|
|||
|
N = 10,410. B = standardized coefficient; CI = confidence interval; OR = odds ratio (shown only for significant predictors). aReference category is for-profit treatment programs. *p < .05, **p < .01 |
|||
|
Ducharme and Abraham Substance Abuse Treatment, Prevention, and Policy 2008 3:17 doi:10.1186/1747-597X-3-17 |
|||
